Carlos Jesus
Dueñas Gutierrez
Hospital Infanta Leonor
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Infanta Leonor (6)
2024
-
Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study
Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607
2023
-
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Viruses, Vol. 15, Núm. 2
-
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Viruses, Vol. 15, Núm. 4
-
Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
Journal of Clinical Medicine, Vol. 12, Núm. 3
2022
-
A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 12, pp. 3519-3523
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252